Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
4,143 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Cardiac Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With First-Line Ibrutinib-Venetoclax.
Hofstetter L, Buchrits S, Sherban A, Sternbach N, Raanani P, Zadok OIB, Gafter-Gvili A, Itchaki G. · Eur J Haematol · 2026 · cited 0 timesmeta-analysis, systematic review
- Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.
Li F, Zhou K, Xu W, Cui G, Yi S, Jin J, Zhu Z, He A, Mi J, Xia Z, Huang X, Zhou X, Yu W, Guo J, Zeng Q, Huang S, Shuang Y, Peng H, Qiu L, Xu B, Li Y, Yang Y, Zhou F, Wang Y, Liu L, Ren J, Li Y, Yang W, Gu J, Ouyang G, Hua L, Zhang J, Xiao Q, Wang S, Zhang Q, Liu J, Ding K, Zhang L, Zeng Y, Li Z, Wen Q, Gao K, Yang H, Jiang Y, Chen Y, Li Z, Tang X, Wang W, Zhao R, Qiu L, Li J. · Signal Transduct Target Ther · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.
Furman RR, Wierda WG, Patten PEM, Chaves JM, Brown JR, Munir T, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos JC, Patel K, Woyach JA, de Borja M, Wang MH, Jain N, O'Brien SM, Byrd JC. · Blood Adv · 2026 · cited 0 timesOpen accessclinical trial, phase ii, multicenter study
- Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.
Swaminathan M, Ferrajoli A, Thompson PA, Burger J, Borthakur G, Takahashi K, Estrov Z, Bharathi V, Bataller A, Kadia TM, Pemmaraju N, Daver N, Jabbour E, Bose P, Kanagal-Shamanna R, Patel KP, Wang SA, Garg N, Hwang H, Wang X, Qiao W, Xu X, Cruz N, Ayala A, Pierce S, Plunkett W, Sampath D, Kantarjian HM, Keating MJ, Gandhi V, Wierda WG, Jain N. · Blood Cancer Discov · 2026 · cited 0 timesclinical trial, phase ii
- Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Botelho SC, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair B, Abada P, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG. · Blood · 2026 · cited 2 timesOpen accessclinical trial, phase ii, multicenter study
- First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.
Caserta S, Martino EA, Lofaro D, Vigna E, Bruzzese A, Mendicino F, Alvaro ME, Labanca C, Lucia E, Olivito V, Amodio N, Morabito F, Gattei V, Gentile M. · Eur J Haematol · 2026 · cited 0 timesOpen accessnetwork meta-analysis
- Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study.
Li J, Yi S, Nguyen T, Yu W, Zhou K, Huang H, Bunworasate U, Huynh M, Zhou H, Yeh SP, Wang Y, Liu X, Fu W, Qiu L. · Ann Hematol · 2026 · cited 1 timesOpen accessclinical trial, phase iii, comparative study
- Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindström V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Böttcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfò L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M, CLL17 Trial Investigators. · N Engl J Med · 2026 · cited 59 timesclinical trial, phase iii, equivalence trial
- Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study.
Lipsky AH, Hill BT, Winter A, Bachow SH, Sender N, Weissbrot H, Viny AD, Rosenblat TL, Heaney ML, Jurcic J, Lamanna N. · Hematol Oncol · 2026 · cited 0 timesclinical trial, phase ii, multicenter study
- Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.
Shadman M, Munir T, Xu S, Yang K, Mohseninejad L, Guthrie G, Hirata J, Lefebure M, Williams R, Tam CS. · Adv Ther · 2026 · cited 0 timesOpen accessmeta-analysis, comparative study
- An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.
Molica S, Giannarelli D, Allsup D. · Leuk Lymphoma · 2026 · cited 0 timescomparative study, systematic review
- Systematic review of real-world data on the effectiveness and safety profiles of first-line therapies in chronic lymphocytic leukemia.
Stożek-Tutro A, Małowicka M, Janiszewska K, Kawalec P. · Crit Rev Oncol Hematol · 2026 · cited 1 timessystematic review, review
- Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia.
Wang L, Kurt M, Disher T, Liu FF, Craigie S, Perna SK, Aronitz E, Eyre TA, Ysebaert L, Davids MS. · Leuk Res · 2025 · cited 0 timesmeta-analysis, systematic review
- Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovská A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Özcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG. · J Clin Oncol · 2026 · cited 19 timesOpen accessclinical trial, phase iii, comparative study
- Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia.
Cabrera-Serrano AJ, Sánchez-Maldonado JM, Rodríguez-Sevilla JJ, Reyes-Zurita FJ, Collado R, Puiggros A, Cornejo-Calvo E, García-Martín P, Ter Horst R, Benavente Y, Jerez A, Landi S, Espinet B, Maffei R, López-Nevot MÁ, Ramos-Campoy S, González-Olmedo C, Chen-Liang TH, Moreno V, Jannus F, Marcos-Gragera R, Carretero-Fernández M, Sampaio-Marques B, Gámez I, García-Álvarez M, Camp NJ, Dierssen-Sotos T, Kamaso J, Pérez EM, Norman AD, Luppi M, Li Y, Alcoceba M, Campa D, de San José S, Marasca R, Ludovico P, Clay-Gilmour A, Canzian F, Ibañez M, Netea MG, McKay J, Casabonne D, Berndt SI, Slager SL, Sainz J. · Blood Adv · 2025 · cited 0 timesOpen accessmeta-analysis
- Prognostic significance of in patients with chronic lymphocytic leukemia: A meta-analysis.
Huang L, Shi X, Tang N, Liu J, Liang Y, Wang X. · Ann Hematol · 2025 · cited 1 timesOpen accessmeta-analysis, review-article
- Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab.
Mu R, Hornick KM, Redekar N, Chen J, Nierman P, Soto S, Herur R, Sun C, Saleh L, Mhibik M, Keyvanfar K, Ahn IE, Wiestner A. · J Immunol · 2025 · cited 2 timesclinical trial, phase ii
- Venetoclax Plus Rituximab for Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis of Treatments Available in Brazil.
Barros BM, Costa MGS, Correia MG, Magliano CS, Lima PVP, Santoni NB, Duva A, Duran MI. · Oncol Ther · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.
Timofeeva N, Herrera B, Fujiwara H, Asami T, Endo H, Hatakeyama M, Nakajima F, Ohmoto H, Nishioka Y, Miyamoto K, Arimura A, Tantawy SI, Pinilla-Ibarz J, Coombs CC, Jain N, Sawa M, Gandhi V. · Blood Cancer J · 2026 · cited 0 timesOpen accessclinical trial
- Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, Gohil S, Paneesha S, Pettitt A, Eyre T, Fox CP, Forconi F, Kennedy B, Balotis C, Pemberton N, Sheehy O, Gribben J, Elmusharaf N, Gatto S, Preston G, Schuh A, Walewska R, Duley L, Webster N, Dalal S, Rawstron A, Howard D, Hockaday A, Jackson S, Greatorex N, Bell S, Stones D, Brown JM, Patten PEM, Hillmen P, UK CLL Trials Group. · N Engl J Med · 2025 · cited 25 timesclinical trial, phase iii, equivalence trial
- Investigating the prognostic value of non-coding RNAs in chronic lymphocytic leukemia: insights from a systematic review and meta-analysis.
Aghayan AH, Arab A, Haddadi S, Mirazimi Y, Hosseinzadeh A, Mohtashami T, Atashi A. · BMC Cancer · 2025 · cited 1 timesOpen accessmeta-analysis, systematic review
- Non-coding RNAs in chronic lymphocytic leukemia: A systematic review and meta-analysis to decode the diagnostic potential.
Aghayan AH, Arab A, Haddadi S, Atashi A. · Mol Cell Probes · 2025 · cited 2 timesmeta-analysis, research support, non-u.s. gov't
- Cardiovascular safety outcomes of chronic lymphocytic leukemia treatments: A systematic and targeted literature review.
Chen YC, Miranda P, Barqawi YK, Fox GE, Chukwu C, Moslehi J, O'Quinn RP. · Crit Rev Oncol Hematol · 2025 · cited 1 timessystematic review
- Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.
Rogers KA, Yan P, Flinn IW, Stephens DM, Kipps TJ, Larson SM, Martz L, Chen X, Wang H, Hopping E, Bundschuh R, Turkoglu A, Lozanski G, McGarry C, Acosta A, Sechaud R, Baldoni D, Chaudhury A, Whalen J, Hassounah NB, Orwitz N, Otero J, Woo J, Byrd JC. · Clin Cancer Res · 2025 · cited 3 timesclinical trial, phase i
- Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.
Ghia P, Rossi D, Ferrant E, de la Cruz Vicente F, Maruyama D, Banerji V, Cobb P, Namburi S, Greil R, Sharman JP, Hess LM, Payakachat N, Bhandari NR, Ruppert AS, Wang D, Abada P, Loubert A, Creel K, Qiao C, Han Y, Hill M, Leow CC, Coombs CC, Barr PM. · J Geriatr Oncol · 2026 · cited 0 timesclinical trial, phase iii, comparative study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.